Staphylococcus Aureus Bacteremia (SAB) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Staphylococcus Aureus Bacteremia (SAB) Market Outlook

Thelansis’s “Staphylococcus Aureus Bacteremia (SAB) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Staphylococcus Aureus Bacteremia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Staphylococcus Aureus Bacteremia (SAB) Overview

Staphylococcus aureus bacteremia (SAB) is a severe bloodstream infection linked to significant illness and death. It leads to various complications, such as infective endocarditis, device-related infections, osteoarticular metastases, pleuropulmonary issues, and recurrent infections. Initially, SAB was categorized into healthcare-associated and community-acquired types. However, with advancements in molecular differentiation and understanding, a new classification emerged: healthcare-associated community-onset. Presently, SAB is categorized into three groups: community-acquired, healthcare-associated community-onset, and healthcare-associated hospital-onset. Community-acquired SAB pertains to individuals without prior healthcare contact, including injection drug users and those with spontaneous osteoarticular infections. These cases often present with multiple complications like endocarditis, renal failure, shock, respiratory distress, or disseminated intravascular coagulation. Healthcare-associated community-onset SAB encompasses patients with recent healthcare exposure, such as hospitalization within the past 90 days, receiving intravenous therapy, wound care, skilled nursing, or residing in healthcare facilities. Healthcare-associated hospital-onset SAB refers to infections contracted within healthcare settings. It is commonly associated with central-line infections, ventilator-associated pneumonia, or surgical site infections. Methicillin-resistant strains often cause these cases and are a leading cause of nosocomial infections. Risk factors for SAB include age, underlying medical conditions, injection drug use, and the presence of intravascular catheters or prosthetic devices. Early recognition of these factors is crucial during patient assessment. SAB can be classified as complicated or uncomplicated. Uncomplicated cases are defined by exclusion of endocarditis, absence of implanted prostheses, negative follow-up blood cultures, defervescence within 72 hours of antibiotic therapy, and no evidence of metastatic infection. Complications of SAB may involve the central nervous system, embolic phenomena, metastatic infections, or recurrent infections within 12 weeks. Predictors of complicated SAB include community acquisition, persistently positive blood cultures, persistent fever, and systemic skin findings. Uncomplicated SAB typically requires at least two weeks of intravenous antibiotic therapy, while complicated cases necessitate four to six weeks. Treatment selection depends on methicillin susceptibility, with preferred agents including penicillinase-resistant penicillins, first-generation cephalosporins, vancomycin, and daptomycin. Beta-lactams, particularly anti-staphylococcal penicillins like nafcillin, are commonly used as first-line agents for MSSA bacteremia.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: